Adiponectin and its response to thiazolidinediones are associated with insulin-mediated glucose metabolism in type 2 diabetic patients and their first-degree relatives

Diabetes, Obesity and Metabolism

Volumn 10, Issue 11, 2008, Pages 1019-1028

  Hulstrom V ^a   Hojlund K ^b   Vinten, J ^a   Beck Nielsen, H ^b   Levin, Klaus ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adiponectin; First degree relatives; Insulin resistance; Non oxidative glucose metabolism; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; GLYCOGEN SYNTHASE; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; TROGLITAZONE;

ADULT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INSULIN INFUSION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RELATIVE; UPREGULATION;

EID: 54249107488     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00854.x     Document Type: Article

References (52)

1. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
2. Whitehead JP, Richards AA, Hickman IJ, MacDonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
3. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
4. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
5. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
6. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
7. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888.
8. Salmenniemi U, Zacharova J, Ruotsalainen E et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 4216-4223.
9. Lattuada G, Costantino F, Caumo A et al. Reduced whole-body lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients. Diabetologia 2005; 48: 741-747.
10. Kowalska I, Straczkowski M, Nikolajuk A, Krukowska A, Kinalska I, Gorska M. Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean non-diabetic offspring of type 2 diabetic subjects. Eur J Endocrinol 2006; 154: 319-324.
11. Pellme F, Smith U, Funahashi T et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182-1186.
12. Civitarese AE, Jenkinson CP, Richardson D et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 2004; 47: 816-820.
13. Lihn AS, Ostergard T, Nyholm B, Pedersen SB, Richelsen B, Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003; 284: E443-E448.
14. Johanson EH, Jansson PA, Lonn L et al. Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 4232-4238.
15. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
16. Højlund K, Frystyk J, Levin K, Flyvbjerg A, Wojtaszewski JF, Beck-Nielsen H. Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006; 49: 1283-1291.
17. Yokoyama H, Emoto M, Mori K et al. Plasma adiponectin level is associated with insulin-stimulated nonoxidative glucose disposal. J Clin Endocrinol Metab 2006; 91: 290-294.
18. Tonelli J, Li W, Kishore P et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621-1629.
19. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.
20. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-206.
21. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
22. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003; 52: 753-759.
23. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
24. Kubota N, Terauchi Y, Kubota T et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006; 281: 8748-8755.
25. Højlund K, Beck-Nielsen H. Impaired glycogen synthase activity and mitochondrial dysfunction in skeletal muscle: Markers or mediators of insulin resistance in type 2 diabetes? Curr Diabetes Rev 2006; 4: 375-395.
26. McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 1976; 41: 565-573.
27. Levin K, Hother-Nielsen O, Henriksen JE, Beck-Nielsen H. Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes. Diabetes Care 2005; 27: 148-154.
28. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
29. Tappy L, Owen OE, Boden G. Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 1988; 37: 1212-1216.
30. Steele R. Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959; 82: 420-430.
31. Rossetti L, Lee YT, Ruiz J, Aldridge SC, Shamoon H, Boden G. Quantitation of glycolysis and skeletal muscle glycogen synthesis in humans. Am J Physiol 1993; 265: E761-E769.
32. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6: 45-86.
33. Kushner RF, Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr 1986; 44: 417-424.
34. Mandarino LJ, Wright KS, Verity LS et al. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. J Clin Invest 1987; 80: 655-663.
35. Thomas JA, Schlender KK, Larner J. A rapid filter paper assay for UDP-glucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. Anal Biochem 1968; 25: 486-499.
36. Toivonen E, Hemmila I, Marniemi J, Jorgensen PN, Zeuthen J, Lovgren T. Two-site time-resolved immunofluorometric assay of human insulin. Clin Chem 1986; 32: 637-640.
37. Goldfine AB, Bouche C, Parker RA et al. Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. Proc Natl Acad Sci U S A 2003; 100: 2724-2729.
38. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
39. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55: 249-259.
40. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acr p30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
41. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acr p30. J Clin Invest 2001; 108: 1875-1881.
42. Stefan N, Stumvoll M, Vozarova B et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26: 3315-3319.
43. Kim YB, Cieraldi TP, Kong A et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51: 443-448.
44. Miyazaki Y, He H, Mandarino LJ, Defronzo RA. Rosiglitazone improves downstream insulin receptor signalling in type 2 diabetic subjects. Diabetes 2003; 52: 1943-1950.
45. Meyer MM, Levin K, Grimmsmann T et al. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 2002; 51: 2691-2697.
46. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-831.
47. Hother-Nielsen O, Henriksen JE, Staehr P, Beck-Nielsen H. Labelled glucose infusate technique in clamp studies. Is precise matching of glucose specific activity important? Endocrinol Metab 1995; 2: 275-287.
48. Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia 1990; 33: 603-610.
49. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
50. Dea MK, Van Citters GW, Ader M, Mittelman SD, Sunehag AL, Bergman RN. Paradoxical effect of troglitazone in normal animals: Enhancement of adipocyte but reduction in liver insulin sensitivity. Diabetes 2000; 49: 2087-2093.
51. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor by nuclear receptors. Diabetes 2003; 52: 1655-1663.
52. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.